Senisca Ltd., a spinout from the University of Exeter, has raised an additional £3.7 million (US$4.7 million) in funding to support the development of RNA-based senotherapeutics to treat age-related disease.
Asgard Therapeutics AB has raised €30 million (US$32.8 million) in a series A round to advance a novel approach to cancer immunotherapy, in which it is proposed to reprogram cancer cells into functional antigen-presenting dendritic cells in vivo, activating a host immune response against the tumor.
Sooma Oy recently raised €5 million (US$5.4 million) in funding to help the company expand access to its transcranial direct current stimulation device which allows patients to treat their depression at home. “This is a significant milestone for us that enables us to help more patients globally and help us develop the company to serve the unmet need,” Tuomas Neuvonen, Sooma's co-founder and CEO, told BioWorld.
Antibody-drug conjugate (ADC) specialist Tubulis GmbH has closed a hefty €128 million (US$139.4 million) series B2 round, more than double the €60 million it raised in its series B1 two years ago.
Atrogi AB is raising a €30 million to €35 million (US$32.9 million to $38.4 million) series B round after announcing positive clinical data for ATR-258, a novel beta-2 adrenergic receptor agonist that is being lined up as a potential first-in-class insulin-independent treatment for type 2 diabetes.
Asgard Therapeutics AB has raised €30 million (US$32.8 million) in a series A round to advance a novel approach to cancer immunotherapy, in which it is proposed to reprogram cancer cells into functional antigen-presenting dendritic cells in vivo, activating a host immune response against the tumor.
Asgard Therapeutics AB has announced a €30 million (US$32.7 million) series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology.
RSS
